Press Releases

Date Title
June 10, 2021 Progenity Announces $40 Million Private Placement
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting
June 2, 2021 Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022 Continuing to seek opportunities to generate
May 26, 2021 Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics
May 25, 2021 Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations. In this advisory role, Dr.
May 24, 2021 Progenity Announces Poster Presentations at Digestive Disease Week 2021
Two Abstracts Support Company’s Targeted Therapeutics Program including the Drug Delivery System SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted
May 21, 2021 Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
Provides educational resources for both patients and healthcare providers SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc . (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health,
May 13, 2021 Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with verification study and demonstrated commercial laboratory systems readiness Announced funding from the Crohn’s
May 12, 2021 Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced
May 11, 2021 Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn’s & Colitis Foundation’s IBD
May 6, 2021 Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13,
Displaying 1 - 10 of 74